Tracer library / [18F]DPA-714
[18F]DPA-714
Also written as [18F]DPA-714; [18F]DPA714; [F-18]DPA-714; [F-18]DPA714; DPA-714
- Radionuclide
- F-18 t½ 109.77 min
- Modality
- PET
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 6
What it is
- Compound class
- Radiolabelled pyrazolo[1,5-a]pyrimidine acetamide (second-generation TSPO ligand)
- Target / mechanism
- 18-kDa translocator protein (TSPO), a marker of activated microglia/macrophages in neuroinflammation PMID 19223401
- Clinical application
- Neuroinflammation / microglial activation imaging in neurological disorders PMID 34037896
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| TRACERlab FX FN GE HealthCare | — | HPLC | 24 ± 3% | — | tosylate substrate | 24615467 2014 Eur J Nucl Med Mol Imaging Automated synthesis of 18F-DPA-714 was carried out using a slightly modified TRACERLab FX-FN module (GE Medical Systems). - The yield was 24 ± 3% with a specific activity of 41–107 GBq/μmol (n = 8). |
| Synthera IBA | vendor cassette | HPLC+SPE | 24.6 ± 3.8% not corrected | > 99.9% | N,N-Diethyl-2-(2-(4-(2-toluenesulfonyloxyeth…N,N-Diethyl-2-(2-(4-(2-toluenesulfonyloxyethoxy)phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide ABX | 38461627 2024 Appl Radiat Isot an automated Synthera® radiosynthesizer (Version 1, IBA Molecular) employing an Integrated Fluidic Processor™ (IFP) cassette - EOS activity yield of 24.6 ± 3.8% and a molar activity of > 18.5 TBq/mmol (500 Ci/mmol) |
| ELIXYS FLEX/CHEM Sofie | — | HPLC+SPE | 13.5 ± 3.04% not corrected | — | 2-(4-(3-(2-(diethylamino)-2-oxoethyl)-5,7-di…2-(4-(3-(2-(diethylamino)-2-oxoethyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-2-yl)phenoxy)ethyl 4-methylbenzenesulfonate In-house / non-commercial (various) | 34871885 2022 Appl Radiat Isot Elixys Flex/Chem (Sofie Biosciences \u2013 Dulles, VA) - [18F]DPA-714 was synthesized in a 13.5 ± 3.04% activity yield (EOS) |
| AllinOne (AiO) Trasis | custom manifold | HPLC+SPE | 55-71 decay-corrected | 100 | DPA-714 tosylate PharmaSynth AS, Tartu, Estonia | 34037896 2021 EJNMMI Radiopharm Chem synthesised using an in-house designed cassette and sequence - [18F]DPA-714 was obtained with consistently high radiochemical yields of 55-71% (n=6) |
| iMiDEV PMB-Alcen | vendor cassette | HPLC | 17 ± 6% decay-corrected | >99% | TsO-DPA-714 PharmaSynth AS, Tartu, Estonia | 39692929 2024 EJNMMI Radiopharm Chem the iMiDEV™ radiosynthesiser - RCYa–17 ± 6%10 ± 1%11% |
| TRACERlab FX FN GE HealthCare | — | — | — | — | — | 22104496 2012 Appl Radiat Isot using a TRACERlab FX-FN synthesizer |
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- ABX, In-house / non-commercial (various), PharmaSynth AS
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [18F]DPA-714, or handle the enquiry for you.
Get in touchQuality control Preliminary - inferred from compound class
- Ph. Eur. monograph
- not verified No Ph. Eur. check is recorded for this entry.
- USP monograph
- not verified No USP check is recorded for this entry.
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [18F]DPA-714.
Get in touchNotes
Added from reverse module search (stage 6); 8 article(s) with F-18. Stage set/updated at stage 39 from PMID 34037896: 'boosting reliability, throughput, and introducing a significant degree of simplicity'.